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Background
The cGMP/cGMP-dependent protein kinase type I (cGKI)
signaling pathway is activated by nitric oxide (NO),
natriuretic peptides (ANP, BNP & CNP), and cGMP-ele-
vating drugs. It regulates important physiological functions
such as platelet aggregation, smooth muscle tonus, and
cell growth and survival. Recent reports indicate that
cGMP might also play a role in tumorigenesis. In the pre-
sent study we found that cGKI is expressed in melanoma
cells of murine and human origin.
Results
Treatment of intact mouse B16 melanoma cells with the
membrane-permeable cGMP analog 8-Br-cGMP induced
phosphorylation of the cGKI substrates, vasodilator-stimu-
lated phosphoprotein and phosphodiesterase 5. ANP and
CNP, ligands of the membrane-bound guanylyl cyclase
GC-A and GC-B, respectively, activated the endogenous
cGMP/cGKI pathway. CNP-induced cGMP signals were
detected in cell extracts by ELISA and in living cells by a
FRET-based cGMP sensor [1]. DEA/NO, which stimulates
NO-sensitive soluble guanylyl cyclase, did not increase
cGMP signaling in B16 cells. Interestingly, activation of
cGMP/cGKI signal transduction was associated with an
increase in ERK1/2 and p38 phosphorylation, growth and
migration of B16 melanoma cells. Similar results were
obtained with WM1205 human melanoma cells.
Conclusion
We have identified a natriuretic peptide/cGMP/cGKI
pathway in melanoma cells, which stimulates tumor cell
growth and migration in vitro. Pharmacologic inhibition
of cGMP signaling may offer a promising strategy for the
treatment of melanoma.
Authors’ details
1Interfakultäres Institut für Biochemie, University of Tübingen, Tübingen,
Germany. 2Department of Preclinical Imaging and Radiopharmacy,
Laboratory for Preclinical Imaging and Imaging Technology of the Werner
Siemens-Foundation, University of Tübingen, Tübingen, Germany.
3Department of Dermatology, University of Tübingen, Tübingen, Germany.
Published: 29 August 2013
Reference
1. Russwurm M, Mullershausen F, Friebe A, Jager R, Russwurm C, Koesling D:
Design of fluorescence resonance energy transfer (FRET)-based cGMP
indicators: a systematic approach. Biochem J 2007, 407:69-77.
doi:10.1186/2050-6511-14-S1-P19
Cite this article as: Dhayade et al.: A novel role of the natriuretic
peptide/cGMP/cGKI pathway in melanoma cells. BMC Pharmacology and
Toxicology 2013 14(Suppl 1):P19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
* Correspondence: sandeep.dhayade@uni-tuebingen.de
1Interfakultäres Institut für Biochemie, University of Tübingen, Tübingen,
Germany
Full list of author information is available at the end of the article
Dhayade et al. BMC Pharmacology and Toxicology 2013, 14(Suppl 1):P19
http://www.biomedcentral.com/2050-6511/14/S1/P19
© 2013 Dhayade et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
